0001209191-23-038409.txt : 20230620
0001209191-23-038409.hdr.sgml : 20230620
20230620163110
ACCESSION NUMBER: 0001209191-23-038409
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230615
FILED AS OF DATE: 20230620
DATE AS OF CHANGE: 20230620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Molineaux Christopher P.
CENTRAL INDEX KEY: 0001654773
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 231025636
MAIL ADDRESS:
STREET 1: C/O ACLARIS THERAPEUTICS, INC.
STREET 2: 101 LINDENWOOD DRIVE, SUITE 400
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-15
0
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001654773
Molineaux Christopher P.
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE
PA
19087
1
0
0
0
0
Common Stock
2023-06-15
4
M
0
51
0.72
A
31805
D
Common Stock
2023-06-15
4
M
0
198
1.52
A
32003
D
Stock Option (right to buy)
0.72
2023-06-15
4
M
0
51
0.00
D
2024-08-12
Common Stock
51
0
D
Stock Option (right to buy)
1.52
2023-06-15
4
M
0
198
0.00
D
2024-12-07
Common Stock
198
0
D
25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.
25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.
/s/ Mark Ballantyne, Attorney-in-Fact
2023-06-20